Holen Sie sich die Stockscreener-App
165.47
1.22%
2.30
Repligen Corp Aktie (RGEN) Neueste Nachrichten
Repligen Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript - AlphaStreet
Is Repligen Corp (RGEN) Undervalued After Q2 Earnings Beat? EPS - GuruFocus
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09 - scanx.trade
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance - TradingView
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance - Quiver Quantitative
Repligen: Q2 Earnings Snapshot - Yahoo Finance
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen Corp (RGEN) Institutional Confidence - TradingKey
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Repligen Corp (RGEN) Cash Flow - TradingKey
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Repligen Corp (RGEN) Income Statement - TradingKey
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corp (RGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RGEN|Repligen Corp|Price:130.800|Chg%:-1.160 - TradingKey
RGEN|Repligen Corp|Price:130.951|Chg%:-1.009 - TradingKey
Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story! - Smartkarma
Repligen Corporation (RGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Daily Brief Health Care: Shanghai Shengsheng Pharmaceutical Cold Chain Technology, Akeso, Mitesco Inc, Nagaileben, Repligen Corp, Scribe Therapeutics, Cosmos Health and more - Smartkarma
Is Repligen Corp (RGEN) a Bargain After 4.1% Drop? GF Value Says Undervalued - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Repligen Corporation to Acquire BioLife Solutions for $1.5 Billion, Boosting Cell Therapy Market Presence - Kalkine Media
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-and-stock deal - Stock Titan
Repligen Corp (RGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research
Canaccord reiterates Hold on Repligen stock after BioLife deal By Investing.com - Investing.com India
RGEN stock holds steady as Repligen backs 2026 growth - Ad-hoc-news.de
Canaccord reiterates Hold on Repligen stock after BioLife deal - Investing.com
Bothell firm fetches $1.5 billion in acquisition by Massachusetts company - The Business Journals
Repligen to Acquire BioLife Solutions for $1.5 Billion, Expanding Leadership in Cell Therapy Market - Minichart
Repligen to Acquire Bothell's BioLife Solutions in $1.5B Deal - 425business.com
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in $1.5B cash-stock deal - Stock Titan
Repligen to Acquire BioLife Solutions for $11.25 per Share Plus Stock, Enhancing Cell Processing Capabilities - Kalkine Media
US759916AC3 Bond Profile — Key Metrics - TradingView
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach - Yahoo Finance
Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business - ETPharma.com
Repligen targets cell therapy expansion as Waltham firm inks $1.5 billion acquisition - The Business Journals
Repligen to Acquire BioLife Solutions in $1.5 Billion Cash-and-Stock Deal, Expanding Into Cell Therapy - finance.biggo.com
Repligen beefs up cell therapy business with $1.5 billion deal for BioLife - Reuters
Repligen Announces Acquisition of BioLife Solutions in $11.25 Per Share Cash and Stock Deal - Kalkine Media
Repligen to Acquire BioLife Solutions in Cash and Stock Merger Valued at $11.25 Per Share - Kalkine Media
What's Going on With Repligen Stock Wednesday?Repligen (NASDAQ:RGEN), BioLife Solutions (NASDAQ:BLFS) - Benzinga
Repligen Corporation (Nasdaq: RGEN) sets cash–stock deal to buy BioLife - Stock Titan
Repligen to Acquire BioLife Solutions in Cash-and-Stock Deal; $11.25 Plus 0.1442 Shares Per Share - TradingView
Repligen Corp: If Deal Terminated Under Some - Moomoo
Repligen to Acquire BioLife Solutions in $1.5 Billion Deal - sekbernews.id
Repligen Corp To Acquire BioLife Solutions Transcript - GuruFocus
Repligen to buy cell therapy maker BioLife in $1.5 billion deal - MSN
Repligen to acquire BioLife Solutions for $1.5 billion - Investing.com
BioLife’s Biopreservation Media Supports 18 Commercially Approved Therapies - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo Finance
A Look at Repligen Corp (RGEN) After 5.9% Decline -- GF Value $1 - GuruFocus
Why Repligen (RGEN) Stock Is Trading Lower Today - Yahoo Finance
Repligen to buy BioLife Solutions (NASDAQ: BLFS) in cash and stock merger - Stock Titan
Form 4 Repligen Corporation For: 17 July By Investing.com - Investing.com South Africa
Repligen CFO Jason K Garland sells $79,500 in stock - Investing.com UK
Repligen CFO Jason K Garland sells $79,500 in stock By Investing.com - Investing.com Nigeria
Repligen CFO Jason Garland Sells 530 Shares Under Pre-Arranged Rule 10b5-1 Trading Plan - Kalkine Media
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN) - GuruFocus
0.40%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):